Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.

@article{Romero2012PharmacokineticpharmacodynamicMO,
  title={Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.},
  author={Elba Ortiz Romero and Nieves V{\'e}lez de Mendiz{\'a}bal and Josep-Mar{\'i}a Cendr{\'o}s and Concepci{\'o}n Peraire and Emma Bascompta and Rosendo Obach and I{\~n}aki F. Troc{\'o}niz},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2012},
  volume={342 3},
  pages={788-98}
}
The objectives of the current work were to develop a predictive population pharmacokinetic (PK)/pharmacodynamic (PD) model for the testosterone (TST) effects of triptorelin (TRP) administered in sustained-release (SR) formulations to patients with prostate cancer and determine the minimal required triptorelin serum concentration (C(TRP_min)) to keep the testosterone levels of the patients below or equal to the level of castration (TST ≤ 0.5 ng/ml). A total of eight healthy male volunteers and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…